Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Br J Haematol
; 204(1): 16-18, 2024 01.
Article
en En
| MEDLINE
| ID: mdl-37957927
ABSTRACT
Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2024;204206-220.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Leucemia Mieloide Aguda
/
Trastornos Mieloproliferativos
Límite:
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article